|Bid||5.81 x 900|
|Ask||6.70 x 800|
|Day's Range||6.51 - 6.95|
|52 Week Range||5.10 - 8.60|
|Beta (3Y Monthly)||-2.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2019 - Apr 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
The agreement will be subject to standard closing conditions and approvals, including certain regulatory approvals. BIMI plans for Boqi Zhengji Pharmacy to operate as a wholly-owned subsidiary led by its existing management team.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales haveRead More...